Key Specifications Table
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|5.09105.0001||Glass bottle||10 mg||
|Overview||A cell-permeable BP-1-102 (Cat. no. 573132) analog that targets STAT3 and STAT5 with comparable affinity and is 4-fold more potent in competing against phosphopeptide for binding SH2 domain of STAT3 over STAT1, exhibiting little potency against upstream kinases or the activation of 21 GPCRs, and displaying much reduced or no affinity toward other kinases in a 101-panel screen. Selectively inhibits cellular STAT3 Y705, but not S727, phosphorylation (0.5 to 5 µM) and is a more potent anticancer agent than BP-1-102 against gliobalstoma (GMB) patients-derived brain tumor stem cell (BTSC) in cultures (IC50 from 42 to 530 nM). Reported to penetrate blood-brain-barrier in mice and effectively inhibit BT73 glioma proliferation in xenografted murine brain (10 mg/kg/d via i.p.; 4 d on/ 3 d off) in vivo.|
|Synonyms||4-(N-(4-Cyclohexylbenzyl)-2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)acetamido)benzoic acid, STAT3 Inhibitor XIX, STAT5 Inhibitor IV, SH-04-54, SH0454, SH454|
|References||Haftchenary, S., et al. 2013. ACS Med. Chem. Lett. 4, In press.|
|Structure formula Image|
|Purity||≥94% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
|Haftchenary, S., et al. 2013. ACS Med. Chem. Lett. 4, In press.|
|JAK/STAT Signaling Research Focus|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.